When initiating therapy, Abbey describes a cautious approach, typically treating the worse-seeing eye first rather than performing bilateral injections at the initial visit. After observing the ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

A team of University of Michigan investigators reported that their multimodal, chronic disease self-management support program for people living with glaucoma, SEE, was linked to an approximate 20% ...

Desk workers reported 99.2 hours of weekly screen time, with weekday exposure comprising 93% of waking hours, underscoring ...

Pitha and colleagues observed a general correlation between patterns of ophthalmic medication and total drug shortage reports in the US. Though ophthalmic drug shortages accounted for 15% of all ...

The 6-month Support, Educate, Empower (SEE) program was associated with a 20% improvement in glaucoma treatment adherence and reduced distress among adult patients. University of Utah data show US ...

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Ocugen has completed enrollment in liMeliGhT, its phase 3 clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGhT as a 1-year clinical trial that will ...

At the EnVision Summit 2025 in San Juan, Puerto Rico, Tania Tai, Lucy Shen, and Shivani Kamat all gave insight into complications they have seen while performing glaucoma surgery. At the Envision ...

In this podcast, Philadelphia cornea and glaucoma surgeon Brian Shafer, MD, discusses the procedures and processes involved ...

The conversation explored DME subtypes, treatment selection, and the roles of VEGF, ANG2, and inflammatory cytokines—particularly in severe or poorly controlled patients who respond inadequately to ...